ACADIA Pharmaceuticals Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über ACADIA Pharmaceuticals Inc Unternehmen

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

ACADIA Pharmaceuticals Inc Informationen



BörsenkürzelACAD

Name des UnternehmensACADIA Pharmaceuticals Inc

IPO-datumMay 27, 2004

CEOMs. Catherine Owen Adams

Anzahl der mitarbeiter653

WertpapierartOrdinary Share

GeschäftsjahresendeMay 27

Addresse12830 El Camino Real

StadtSAN DIEGO

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl92130

Telefon18585582871

Websitehttps://acadia.com/

BörsenkürzelACAD

IPO-datumMay 27, 2004

CEOMs. Catherine Owen Adams

Führungskräfte von ACADIA Pharmaceuticals Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Julian C. Baker

Independent Director

102.88K

--

Dr. Adora Ndu, Pharm.D.

Independent Director

24.80K

+60.90%

Ms. Laura A. Brege

Independent Director

15.10K

-48.90%

Mr. James Michael (Jim) Daly

Independent Director

--

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Chairman of the Board

--

Dr. Elizabeth H. Z. Thompson, Ph.D.

Executive Vice President and Head of Research and Development

--

Mr. Mark C. Schneyer

Chief Financial Officer, Executive Vice President

--

Dr. Edmund P. Harrigan

Independent Director

--

Mr. Thomas Andrew (Tom) Garner

Executive Vice President, Chief Commercial Officer

--

Ms. Catherine Owen Adams

Chief Executive Officer, Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Julian C. Baker

Independent Director

102.88K

--

Dr. Adora Ndu, Pharm.D.

Independent Director

24.80K

+60.90%

Ms. Laura A. Brege

Independent Director

15.10K

-48.90%

Mr. James Michael (Jim) Daly

Independent Director

--

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Chairman of the Board

--

Dr. Elizabeth H. Z. Thompson, Ph.D.

Executive Vice President and Head of Research and Development

--

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q2

FY2023Q1

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

NUPLAZID

168.48M

63.68%

DAYBUE

96.09M

36.32%

Keine Daten

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

NUPLAZID

168.48M

63.68%

DAYBUE

96.09M

36.32%

Aktionärsstatistik

Aktualisiert: Wed, Oct 8

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Baker Bros. Advisors LP

25.36%

BlackRock Institutional Trust Company, N.A.

10.77%

The Vanguard Group, Inc.

8.96%

RTW Investments L.P.

5.32%

State Street Investment Management (US)

3.65%

Andere

45.95%

Aktionäre

Anteil

Baker Bros. Advisors LP

25.36%

BlackRock Institutional Trust Company, N.A.

10.77%

The Vanguard Group, Inc.

8.96%

RTW Investments L.P.

5.32%

State Street Investment Management (US)

3.65%

Andere

45.95%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

36.76%

Investment Advisor

34.34%

Investment Advisor/Hedge Fund

25.10%

Research Firm

3.90%

Pension Fund

1.27%

Sovereign Wealth Fund

0.91%

Individual Investor

0.56%

Bank and Trust

0.34%

Venture Capital

0.06%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

670

173.25M

102.40%

-15.51M

2025Q2

671

174.83M

104.44%

-12.86M

2025Q1

688

177.74M

106.20%

-7.86M

2024Q4

643

167.35M

100.34%

-11.57M

2024Q3

599

161.17M

97.17%

-22.69M

2024Q2

603

166.04M

100.49%

-20.26M

2024Q1

612

167.37M

101.58%

-15.73M

2023Q4

589

164.89M

100.43%

-16.10M

2023Q3

560

161.37M

98.56%

-19.17M

2023Q2

557

164.35M

101.06%

-15.99M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Baker Bros. Advisors LP

42.90M

25.43%

+18.77K

+0.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

18.22M

10.8%

-552.34K

-2.94%

Jun 30, 2025

The Vanguard Group, Inc.

15.24M

9.03%

+61.01K

+0.40%

Jun 30, 2025

RTW Investments L.P.

9.00M

5.33%

+455.43K

+5.33%

Jun 30, 2025

State Street Investment Management (US)

6.18M

3.66%

-815.47K

-11.66%

Jun 30, 2025

Morgan Stanley & Co. LLC

3.19M

1.89%

-1.07M

-25.06%

Jun 30, 2025

Point72 Asset Management, L.P.

3.17M

1.88%

-1.48M

-31.74%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.02M

1.79%

+69.58K

+2.36%

Jun 30, 2025

Citadel Advisors LLC

3.01M

1.79%

+2.72M

+922.43%

Jun 30, 2025

Palo Alto Investors LP

2.56M

1.52%

-100.72K

-3.78%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Alger Weatherbie Enduring Growth ETF

3.79%

iShares Neuroscience and Healthcare ETF

3.51%

First Trust NYSE Arca Biotechnology Index Fund

3.16%

Invesco Biotechnology & Genome ETF

2.22%

ALPS Medical Breakthroughs ETF

2.12%

Invesco S&P SmallCap Health Care ETF

1.69%

Virtus LifeSci Biotech Products ETF

1.63%

Invesco S&P SmallCap 600 GARP ETF

1.14%

SPDR S&P Biotech ETF

1.07%

Invesco S&P SmallCap Quality ETF

0.67%

Alger Weatherbie Enduring Growth ETF

Anteil3.79%

iShares Neuroscience and Healthcare ETF

Anteil3.51%

First Trust NYSE Arca Biotechnology Index Fund

Anteil3.16%

Invesco Biotechnology & Genome ETF

Anteil2.22%

ALPS Medical Breakthroughs ETF

Anteil2.12%

Invesco S&P SmallCap Health Care ETF

Anteil1.69%

Virtus LifeSci Biotech Products ETF

Anteil1.63%

Invesco S&P SmallCap 600 GARP ETF

Anteil1.14%

SPDR S&P Biotech ETF

Anteil1.07%

Invesco S&P SmallCap Quality ETF

Anteil0.67%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten